Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

240P - Feasibility of detecting NSCLC-associated fusion genes in long-term preserved FFPE samples

Date

22 Mar 2024

Session

Poster Display session

Topics

Pathology/Molecular Biology

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Dongmei Lin

Citation

Annals of Oncology (2024) 9 (suppl_3): 1-6. 10.1016/esmoop/esmoop102579

Authors

D. Lin1, Q. Feng2, Y. Wang2, D. Qiao2, X. Li3, L. Xu3, C. Zhu3

Author affiliations

  • 1 Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing/CN
  • 2 Peking University Cancer Hospital & Institute, Beijing/CN
  • 3 Amoy Diagnostics, Xiamen, China, Xiamen/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 240P

Background

mRNA testing in NSCLC patients enhances the detection of mutations like ALK, RET, ROS1, and MET exon14 skipping. Due to mRNA's vulnerability to degradation, strict testing standards are required. The current consensus is that samples stored for less than three years are suitable for detection and treatment guidance. However, the suitability of longer-stored samples for mRNA-based fusion testing remains uncertain. This study evaluates the efficacy of AmoyDx 11-gene PCR in detecting fusion genes in long-term preserved FFPE samples.

Methods

We retrospectively analyzed 119 FFPE samples from NSCLC patients collected between 2015 and 2022, which had undergone target sequencing at collection. mRNA was re-extracted and its concentration measured using UV spectrophotometry, followed by AmoyDx 11-gene PCR fusion gene detection.

Results

The study included samples previously identified as ALK fusion (n=22), MET exon14 skipping (n=16), RET fusion (n=17), ROS1 fusion (n=25), and driver gene-negative (n=39). FFPE samples were categorized into three groups based on storage duration: 2-3 years (n=59), 4 years (n=30), and equal or greater than 5 years (n=30). There was no significant difference in mRNA concentration among the three groups, with median concentration of 113.6 ng/μl (2-3 years), 131.9 ng/μl (4 years), and 88.1 ng/μl (≥ 5 years). PCR successfully detected fusion genes in all samples. 79 driver gene-positive patients were identified: ALK fusion (n=23), MET exon14 skipping (n=15), RET fusion (n=18), ROS1 fusion (n=22). The overall concordance rate was 93.3%, with concordance rates for each group are 97.7% (2-3 years), 100% (4 years), and 80.0% (≥ 5 years), respectively.

Conclusions

PCR effectively detects mRNA in long-term preserved FFPE samples, providing valuable variant information for treatment guidance in NSCLC patients, even after extended storage periods.

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.